Sucesores De Esmoris & Co., Inc.
Letter data
- Company
- Sucesores De Esmoris & Co., Inc.
- Recipient
- Mr. James Fox | President | Sucesores De Esmoris & Co., Inc. | Sucesores De Esmoris & Co., Inc. | 5 Comercio St | Mayaguez | , | PR | 00680 | United States
- Issue date
- 2018-01-02
- Posted date
- Not available
- FDA office
- United States
- Subject
- Not available
- Product
- Not available
- CMS ID
- 518991
- Reference number
- Not available
- FEI
- Not available
- Inspection dates
- Not available
Normalized citations
21 CFR: None found
21 U.S.C.: None found
Related FDA links
No related FDA letter link is present in the source index.
Full source text
CLOSEOUT LETTER
Sucesores De Esmoris & Co., Inc.
MARCS-CMS 518991 —
January 02, 2018
More Warning Letters
Warning Letters
About Warning and Close-Out Letters
Recipient:
Recipient Name
Mr. James Fox
Recipient Title
President
Sucesores De Esmoris & Co., Inc.
Sucesores De Esmoris & Co., Inc.
5 Comercio St
Mayaguez
,
PR
00680
United States
Issuing Office:
United States
787-729-8500
Office of
Office of Human and Animal Food Operations
East Division IV
Compliance Branch
466 Avenida Fernández Juncos
San Juan, Puerto Rico 00901-3223
Tel: (787) 729-850
Office of Regulatory Affairs
Office of Human and Animal Food Operations
East Division IV
Compliance Branch
466 Avenida Fernández Juncos
San Juan, Puerto Rico 00901-3223
Tel:
(787) 729-8500
January 2, 2018
18-HAFE4-WLCOL-02
VIA UNITED PARCEL SERVICE
NEXT DAY - SIGNATURE REQUIRED
Mr. James J. Fox, President
Sucesores de Esmoris & Co., Inc.
5 Comercio St.
Mayagüez, Puerto Rico 00680
Re: Warning Letter, 17-SJN-WL-05 dated 03/07/2017
Dear Mr. Fox:
The Food and Drug Administration has completed an evaluation of your firm’s corrective actions in response to Warning Letter, 17-SJN-WL-05, dated 03/07/2017. It appears that you have addressed the violations contained in this Warning Letter. Future FDA inspections and regulatory activities will further assess the adequacy and sustainability of these corrections.
This letter does not relieve you or your firm from the responsibility of taking all necessary steps to assure sustained compliance with the Federal Food, Drug, and Cosmetic Act and its implementing regulations or with other relevant legal authority. The Agency expects you and your firm to maintain compliance and will continue to monitor your state of compliance. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.
Kind regards,
/S/
Beira Montalvo
Acting, Director of Compliance Branch
OHAFO East Division IV
Content current as of:
01/04/2018